<?xml version="1.0"?>
<law><site_title>Virginia Decoded</site_title><site_url>https://vacode.org</site_url><law_id>86395</law_id><section_number>38.2-3453</section_number><catch_line>Clinical trials</catch_line><edition url="https://vacode.org/2025/" slug="2025" current="TRUE" last_updated="">2025</edition><structure><unit label="title" level="1" order_by="1" identifier="38.2">Insurance</unit><unit label="chapter" level="2" order_by="1" identifier="34">Provisions Relating to Accident and Sickness Insurance</unit><unit label="article" level="3" order_by="1" identifier="6">Federal Market Reforms</unit></structure><text>
						<section id="A"><p><span class="prefix-number">A.</span> Notwithstanding any provision of &#xA7; <a class="law" title="Coverage for clinical trials for treatment studies on cancer" href="/38.2-3418.8/">38.2-3418.8</a> or any other section of this title to the contrary, if a health carrier offering a health benefit plan providing individual or group health <span class="dictionary">insurance</span> coverage provides coverage to a <span class="dictionary">qualified individual</span>, then such plan shall provide for participation in an <span class="dictionary">approved clinical trial</span> and cover <span class="dictionary">routine patient costs</span> for items and services furnished in connection with participation in such clinical trial. The health carrier shall not discriminate against the <span class="dictionary">qualified individual</span> on the basis of his participation in such clinical trial. <a id="paragraph-309415" class="section-permalink" href="https://vacode.org/38.2-3453/#A"><i class="fa fa-link"/></a></p></section>
						<section id="B"><p><span class="prefix-number">B.</span> For purposes of this section: <a id="paragraph-309416" class="section-permalink" href="https://vacode.org/38.2-3453/#B"><i class="fa fa-link"/></a></p></section>
						<section id="B1" class="indent-1"><p><span class="prefix-number">1.</span> &#x201C;<span class="dictionary">Approved clinical trial</span>&#x201D; means a phase I, phase II, phase III, or phase IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-threatening disease or condition, and the study or investigation is (i) a federally funded or approved trial, (ii) conducted under an investigational new drug application reviewed by the U.S. Food and Drug Administration, or (iii) a drug trial that is exempt from having an investigational new drug application. <a id="paragraph-309417" class="section-permalink" href="https://vacode.org/38.2-3453/#B1"><i class="fa fa-link"/></a></p></section>
						<section id="B2" class="indent-1"><p><span class="prefix-number">2.</span> &#x201C;<span class="dictionary">Life threatening condition</span>&#x201D; means any disease or condition from which the likelihood of death is probable unless the course of disease or condition is interrupted. <a id="paragraph-309418" class="section-permalink" href="https://vacode.org/38.2-3453/#B2"><i class="fa fa-link"/></a></p></section>
						<section id="B3" class="indent-1"><p><span class="prefix-number">3.</span> &#x201C;<span class="dictionary">Qualified individual</span>&#x201D; means a covered <span class="dictionary">person</span> who is eligible to participate in an <span class="dictionary">approved clinical trial</span> according to the trial protocol, with respect to treatment of cancer or other life-threatening disease or condition, and the referring health care professional has concluded that the individual&#x2019;s participation in such trial is appropriate to treat the disease or condition, or the individual&#x2019;s participation is based on medical and scientific information. <a id="paragraph-309419" class="section-permalink" href="https://vacode.org/38.2-3453/#B3"><i class="fa fa-link"/></a></p></section>
						<section id="B4" class="indent-1"><p><span class="prefix-number">4.</span> &#x201C;<span class="dictionary">Routine patient costs</span>&#x201D; means all items and services consistent with the coverage provided under the health benefit plan that is typically covered for a <span class="dictionary">qualified individual</span> who is not enrolled in a clinical trial. <span class="dictionary">Routine patient costs</span> do not include the investigational item, device, or service itself; items or services that are provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management of the patient; or a service that is clearly inconsistent with widely accepted and established standards of care for a particular diagnosis. <a id="paragraph-309420" class="section-permalink" href="https://vacode.org/38.2-3453/#B4"><i class="fa fa-link"/></a></p></section>
						<section id="C"><p><span class="prefix-number">C.</span> Nothing in this section shall preclude a health benefit plan from requiring that a <span class="dictionary">qualified individual</span> participate in an <span class="dictionary">approved clinical trial</span> through a participating provider if such provider will accept the individual as a participant in the trial. However, a health benefit plan may not preclude a <span class="dictionary">qualified individual</span> from participating in an <span class="dictionary">approved clinical trial</span> conducted outside the <span class="dictionary">state</span> in which the individual resides.
			This section shall not be construed to require that a health benefit plan provide benefits outside of the plan&#x2019;s health care provider network unless out-of-network benefits are otherwise provided under the plan. <a id="paragraph-309421" class="section-permalink" href="https://vacode.org/38.2-3453/#C"><i class="fa fa-link"/></a></p></section>
						<section id="D"><p><span class="prefix-number">D.</span> This section shall not apply to any grandfathered plan providing individual or group health <span class="dictionary">insurance</span> coverage. <a id="paragraph-309422" class="section-permalink" href="https://vacode.org/38.2-3453/#D"><i class="fa fa-link"/></a></p></section></text><history>2013, c. 751.</history><metadata></metadata></law>
